| | 231277-92-2 Basic information More.. |
| Product Name: | Lapatinib | | Synonyms: | lapatinib;n-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]-2-furyl]quinazolin-4-amine;4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-;Lapatinib(TINIBS);Lapatinib Base N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-4-Quinazolinamine;GW2016 LAPATINIB;N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)furan-2-yl)quinazolin-4-amine;N-{3-chloro-4-[(3-fluorobenzyl)oxyl]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)furan-2-yl]quinazolin-4-amine | | CAS: | 231277-92-2 | | MF: | C29H26ClFN4O4S | | MW: | 581.06 | | EINECS: | 1806241-263-5 | | Mol File: | 231277-92-2.mol |  |
Use
Lapatinib, a new member of the 4-anilinoquinazoline class of rtk inhibitors (rtkis), was launched as an oral treatment for breast cancer. lapatinib has dual affinity for egfr and her2 tyrosine kinases. it is indicated in combination with capecitabine for treating patients with advanced or metastatic breast cancer whose tumors overexpress her2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab.
- Lapatinib
-
- US $29.00-50.00 / mg
- 2025-07-02
- CAS:231277-92-2
- Min. Order:
- Purity: 99.89%
- Supply Ability: 10g
- Lapatinib
-
- US $29.00-50.00 / mg
- 2025-07-01
- CAS:231277-92-2
- Min. Order:
- Purity: 99.89%
- Supply Ability: 10g
- Lapatinib
-
- 2025-07-01
- CAS:231277-92-2
- Min. Order:
- Purity: 0.99
- Supply Ability:
|
|
231277-92-2
Recommend Suppliers |
|